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1878-3317/Copyright  2014, Taipei Medical UniversiBackground: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by the synovial
inﬂammation of the joints. Various cells and cytokines have been identiﬁed that may contribute to RA
pathology. Interleukin (IL)-21 is a proinﬂammatory cytokine mediating pleiotropic functions through the
IL-21 receptor (IL-21R). Blockade of IL-21R may represent a hopeful therapeutic approach in RA. The aim
of this study was to determine the percentage of IL-21R expressing CD4þ cells and IL-21 mRNA
expression in peripheral blood of RA patients.
Methods: Surface expression of IL-21R on CD4þ cells in peripheral blood of RA patients (n ¼ 32
compared to healthy control participants (n ¼ 20) was evaluated by ﬂow cytometry. Simultaneously,
mononuclear cells were taken apart from the peripheral blood of individuals on a density gradient. The
expression of IL-21 mRNA was assessed by real-time polymerase chain reaction.
Results: IL-21R-expressing CD4þ cells from RA patients showed a signiﬁcantly higher percentage of IL-
21R compared with healthy controls (p < 0.05). Moreover, real-time polymerase chain reaction showed
that there was no signiﬁcant difference between patients and healthy controls.
Conclusion: Our results indicate higher expression of IL-21R in RA patients and suggest that targeting of
the IL-21R may be a novel therapeutic idea for the treatment of RA.
Copyright  2014, Taipei Medical University. Published by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease with
unclear etiology and pathology, characterized by the inﬁltration of
various inﬂammatory cells into the joints, inﬂammation of synovial
tissues, cartilage destruction, and bone erosions.1e6 RA prevalence
is about 1% of the population worldwide7,8 The milieu of secreted
cytokines is critical in the differentiation and expansion of patho-
genic cells.9,10 Hence the inﬂammatory conditions in RA are
controlled by various cytokines, especially interleukin (IL)-21.11 IL-
21 is a newly discovered proinﬂammatory cytokine contributing
towards autoimmune diseases such as systemic lupus erythema-
tosus, multiple sclerosis, type 1 diabetes, and, especially, in rheu-
matoid arthritis.12e14 It enhances the differentiation of Th17 cellse no conﬂicts of interest.
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ty. Published by Elsevier Taiwan LLand intensify IL-17 production.15,16 IL-21 is a member of the IL-2
family of cytokines chieﬂy produced by activated CD4þ T cells,
comprising Th1, Th2, and Th17 cells.17,18 However, its receptor (IL-
21R) has been observed on various kinds of cells, inﬂuencing on
both innate and adaptive immunity systems.18,19 It augments pro-
liferation and differentiation of CD4þ/ CD8þ T cells and also re-
inforces the activation and propagation of natural killer
cells.1,12,20,21 In addition to regulating the production of antibody,
containing all immunoglobulin G isotypes, IL-21 has a substantial
role in activation, maturation, and clonal expansion of B cells.22e24
Heterodimeric receptor of IL-21 contains IL-21 speciﬁc receptor
plus common g-chain receptor which is structurally associated
with IL-2R, IL-4R, and IL-15R.1,22,23 The role of IL-21 and IL-21R in
human diseases has not been determined precisely.25 However,
blocking of IL-21 and IL-21R has ameliorated synovitis and articular
cartilage damages in animal models of arthritis, such as collagen-
induced arthritis.19,26,27 Therefore, this study was designed to
investigate IL-21-expressing CD4þ cells and the expression of IL-21
mRNA in RA patients in comparison to healthy controls. If IL-21Rþ
cells signiﬁcantly increase in the peripheral blood of RA patients, itC. All rights reserved.
F. Seif et al.58may represent a substantial therapeutic target for the treatment of
human RA.
2. Methods
2.1. Patients and sampling
In this study, 32 patients with RA who fulﬁlled the 1987 revised
criteria of the American College of Rheumatology were totally
included.28 This group consisted of 28 female and 4 male in-
dividuals. The mean  standard deviation age of the patients was
48.5 9.85 years. Twenty healthy individuals matched for sex ratio
and mean age (16 females and 4 males, age 45.8  6.94 years) were
also included as a control group. Written consent was obtained
from all participating individuals prior to sample collection. At the
time of sample collection, recruited patients had been treated with
disease-modifying antirheumatic drugs and steroids.29 However,
these are not a certain cure for RA; medications conventionally
used can relieve inﬂammation and inhibit mitigation of the in-
ﬂammatory cells to the tissue resulting in joint damage reduction.30
The clinical details and medication of patients and healthy controls
who donated whole blood are presented in Table 1. Whole blood
samples were collected from peripheral veins. The protocols of ﬂow
cytometry and RNA extractionwere carried out simultaneously and
cDNA was immediately synthesized, and stored at 70C until it
was used for real-time polymerase chain reaction (PCR).
This studywas approved by the Ethics Committee of Shahrekord
University of Medical Sciences, Shahrekord, Iran.
2.2. Real-time PCR
After gathering heparinized whole blood, peripheral blood mono-
nucleated cells were isolated by FicolleHypaque density centrifu-
gation (Sigma-Aldrich, St Louis, MO, USA). Then, total RNA was
isolated from peripheral bloodmononucleated cells using RNX-Plus
solution (Sinaclon, Tehran, Iran). Genomic DNA was removed from
total RNA using RNase-free DNase Set (Qiagen, Chartsworth, CA,
USA). Reverse transcription reaction was conducted at 25C for 5
minutes, 42C for 60 minutes and 70C for 5 minutes in a 12 mL
mixture containing 4 mg of total RNA, using Revert Aid First cDNA
synthesis kit (Revert Aid First, Fermentas, Finland). Each real-time
PCR was prepared in a 20 mL reaction mixture containing 10 mL
TaqMan Universal PCRMasterMix, 3 mL cDNA, 0.4 mL primers (10pM
each of forward and reverse primers) and 0.2 mL probe (10pM) in
capillary tubes and conducted on a Rotor Gene 3000 (Corbett,
Mortlake, NSW, Australia). Cycling conditions were: initial dena-
turation 5minutes at 95C for the activation of polymerase, followed
by 40 cycles of 15 seconds at 95C, and 60 seconds at 60C. ResultsTable 1 Basic characteristics and medications of RA patients and healthy controls
included in the study
RA patients Healthy controls
Total number 32 20
Men/women 4/28 4/16
Age, y (mean  SD) 48.5  9.85 45.8  6.94
Treatment:
Methotrexate (DMARD)
median dose, mg/wk
7/5e15
Prednisone (steroid)
median dose, mg/d
5e10
Hydroxychloroquine (DMARD)
median dose, mg/d
200e400
Sulfasalazine (DMARD)
median dose, g/d
1e2
DMARD ¼ disease-modifying anti-rheumatic drug; SD ¼ standard deviation.were normalized on the basis of values for b-actin cDNA. The primer
and probe sets (50-FAM-labeled) were purchased from Applied
Biosystems (Foster City, CA, USA). BLAST searches were conducted
on them to ensure gene speciﬁcation. The sequences of the primer
andprobes are summarized inTable 2. All samples of RApatients and
healthy controls were assayed in duplicate. Relative gene expression
was measured by the previously published method.31,32 Negative
controls were also included, containing all the elements of the re-
action mixture other than template DNA.
2.3. Flow cytometry
Antibodies used for ﬂow cytometry were purchased from BD
Pharmingen (San Diego, CA, USA): anti-CD4 conjugated to PE-Cy5
and anti-IL-21R conjugated to allophycocyanin. Brieﬂy, aliquots of
110 mL of the whole blood containing K3EDTA were added and
stained with 20 mL of each monoclonal antibody for 15 minutes at
37C and 15 minutes at room temperature, then erythrocytes were
lysed by adding 1.1 mL of ﬂuorescence-activated cell sorter lysing
solution (Becton Dickinson, Lincoln Park, NJ, USA). After staining,
the cells were washed three times in phosphate-buffered saline
(PBS) and immediately analyzed using ﬂow cytometry (PARTEC,
Münster, Germany). Lymphocytes were gated based on the for-
ward- and side-scatter properties and at least 5000 CD4þ lym-
phocytes were observed. The ﬂow cytometry results were analyzed
using Flow Jo software version 7.6 (Tree Star, Ashland, OR, USA).
2.4. Statistical analysis
Statistical analyses were performed with SPSS version 15.0 (SPSS
Inc., Chicago, Illinois, USA). Data are expressed as mean  standard
deviation. Differences between the two groups were analyzed with
nonparametric ManneWhitney test and presented using Prism
software (GraphPad, La Jolla, California). A value of p < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. IL-21R expressing CD4þ cells
In order to calculate the percentage of IL-21R expressing CD4þ cells,
the collected peripheral blood from RA patients and healthy con-
trols were analyzed using ﬂow cytometry.33 As shown in Figures 1
and 2, peripheral blood CD4þ cells of RA patients revealed a
signiﬁcantly higher percentage of IL-21R (32.47  9.19%) compared
with those in healthy controls (21.73  7.45%; p < 0.05). On the
basis of this ﬁnding, IL-21R may play an important role in the
pathogenesis of RA.
3.2. Expression of IL-21 in total RNA extracts
To understand the potential function of IL-21 in RA, total RNA ex-
tracts derived from peripheral blood of RA patients and also healthy
controls were included in the study. As shown in Figure 3, theTable 2 Sequences of TaqMan primers and probes for the b-actin and interleukin-21
(IL-21) genes
Gene Primer sequences and probes
b-actin Probe: 50-CCGCCGCCCGTCCACACCCGCC-30
Forward: 50-AGCCTCGCCTTTGCCGA-30
Reverse: 50-CTGGTGCCTGGGGCG-30
IL-21 Probe: 50- TCTGCCAGCTCCAGAAGATGTAGAGACAAA-30
Forward: 50-TGTGAATGACTTGGTCCCTGAA-30
Reverse: 50-AGCAGGAAAAAGCTGACCACTCA-30
Figure 1 Expression of IL-21R in peripheral blood on a ﬂow cytometric analysis. Whole blood from either RA patients or healthy controls were stained with either mouse anti-
human CD4 or interleukin-21 receptor (IL-21R) monoclonal antibodies for 15 minutes at 37C followed by 15 minutes at room temperature, then erythrocytes were lysed by
adding 1.1 mL of ﬂuorescence-activated cell sorter lysing solution. After washing three times with phosphate-buffered saline, cells were examined for calculating the percentage of
IL-21R expression on CD4þ cells. (A) Lymphocytes were gated based on the forward and side-scatter properties. (B) At least 5000 CD4þ lymphocytes were analyzed. Shows dot plot
quadrant of IL-21Rþ/CD4þ expressing cells of (C) RA patients and (D) healthy controls.
IL-21R for treatment of rheumatoid arthritis 59expression of IL-21 in RA patients was 0.31  0.58 fold in com-
parison to healthy controls (1  1.4), whereas statistical analyses
demonstrated no signiﬁcant difference between two mentioned
groups.
Our ﬁndings indicate that the medicines taken might affect
expression of IL-21 mRNA but did not inﬂuence IL-21R expression
in CD4þ cells.Patients Healthy controls
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Figure 2 Expression of IL-21R on CD4þ cells. The proportion of interleukin (IL)-21R
expression on CD4þ cells from RA patients and healthy controls is indicated. It shows
the 32 patients in comparison with 20 age-matched healthy controls. The p value was
calculated using nonparametric ManneWhitney test and is signiﬁcant at <0.05.4. Discussion
This study was undertaken to evaluate the expression of IL-21R in
the peripheral blood of RA patients. Therefore, we examined IL-21R
expression on the surface of CD4þ cells. Our results show that thePatient Healthy control
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Figure 3 Level of mRNA for interleukin (IL)-21 was detected by quantitative real-time
polymerase reaction. Gene expression was normalized to b-actin mRNA levels in each
sample. The p value was calculated using nonparametric ManneWhitney test and is
not signiﬁcant at p < 0.05.
F. Seif et al.60expression of IL-21R is signiﬁcantly increased in RA patients
compared with controls. IL-21 is a pleiotropic cytokine inﬂuencing
CD4þ, CD8þ T, B, and NK cells.22,34,35 Phenotypic observations
showed that IL-21R is predominantly expressed in the cell surface
of CD4þ cells19 and is not found on nonlymphoid cells in physio-
logic situations.36 It has been shown that IL-21R is highly expressed
in synovial ﬂuid, cartilage, and bone of RA patients.25 Fröhlich
et al37 displayed the over expression of IL-21R in inﬂamed joints of
RA patients. Also Liu et al38 showed that IL-21R expression was
markedly higher in CD4þ cells EAUmice. Other studies have shown
that IL-21R is upregulated on CD4þ cells.12,34,39 In a similar study,
Liu et al39 compared the numbers of IL-21R-expressing cells in in-
ﬂammatory bowel disease patients who took different medicines
(e.g., sulfasalazine and corticosteroids) and found that these med-
icines did not have an impact on IL-21R expression. These obser-
vations suggest that IL-21R may be effectively involved in RA
progression.
We examined the IL-21 expression in RA patients and found
results provided no evidence of signiﬁcant difference at the mRNA
level using TaqMan real-time PCR in RA patients compared to
controls. IL-21 has been observed to be effective in a variety of
disease conditions.40 Niu et al41 showed that IL-21 was produced at
high levels in the synovial ﬂuid and serum of RA patients and found
a possible role of IL-21. In contrast to the study of Jüngel et al,25
Andersson et al42 detected signiﬁcant higher mRNA level for IL-
21 in RA synovial tissues. Additionally Geri et al43 found a
remarkably increased serum level of IL-21 in peripheral blood from
patients with Behçet disease. Their study showed that IL-21 could
increase the number of Th17 cells and could suppress Treg cells by
decreasing FoxP3 expression.43 Jang et al44 showed that IL-21 could
produce a positive autocrine feedback regulating homeostasis of
activated CD4þ cells; therefore, subsequently it might play an
essential role in the development of autoimmune arthritis. Fantini
et al45 explored high levels of IL-21 expression in inﬂammatory
bowel disease, inhibiting the induction and expansion of Treg cells.
Because a large quantity of patients respond or display little
response to treatment,46 understanding critical roles of various
proinﬂammatory cytokines in the pathogenesis of autoimmune
diseases, especially RA, has led to new therapeutic innovations.47 In
this respect, neutralizing of IL-21 activity with an IL-21ReFc fusion
protein could prevent interferon-g,26,48 IL-625 and increase the
expression of FoxP3.49 Carbone et al50 indicated that blockade of
the IL-6R in RA patients with tocilizumab is associated with a
decreased production of IL-21 bymemory/activated CD4 Tcells. In a
correlated study, the effective amount of the IL-21ReFc
fusion protein required to induce a signiﬁcant effect was reported
as 50e100 mg/mL.30 In another study, blockade of the IL-21
pathway with IL-21R-Fc regained the balance between TH17 cells
and Treg cells.43 Blockade of the IL-21R could ameliorate disease
severity in animal studies. Therefore, targeting against IL-21R may
be attempted as a potential therapeutic in the management of RA
patients.26,37,51
In conclusion, this study demonstrated increased proportions of
IL-21RþCD4þ cells in RA patients, which indicates that IL-21R may
play a pivotal role in RA progression and represents a novel target
for innovative therapy. Further investigations are necessary to
conﬁrm and expand the current results.
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